Discovery of Pyrazolocarboxamides as Potent and Selective Receptor Interacting Protein 2 (RIP2) Kinase Inhibitors
作者:Curt D. Haffner、Adam K. Charnley、Christopher J. Aquino、Linda Casillas、Máire A. Convery、Julie A. Cox、Mark A. Elban、Nicole C. Goodwin、Peter J. Gough、Pamela A. Haile、Terry V. Hughes、Beth Knapp-Reed、Constantine Kreatsoulas、Ami S. Lakdawala、Huijie Li、Yiqian Lian、David Lipshutz、John F. Mehlmann、Michael Ouellette、Joseph Romano、Lisa Shewchuk、Arthur Shu、Bartholomew J. Votta、Huiqiang Zhou、John Bertin、Robert W. Marquis
DOI:10.1021/acsmedchemlett.9b00141
日期:2019.11.14
Herein we report the discovery of pyrazolocarboxamides as novel, potent, and kinase selective inhibitors of receptor interacting protein 2 kinase (RIP2). Fragment based screening and design principles led to the identification of the inhibitor series, and X-ray crystallography was used to inform key structural changes. Through key substitutions about the N1 and C5 N positions on the pyrazole ring significant
在这里,我们报告吡唑并羧酰胺作为受体相互作用蛋白2激酶(RIP2)的新型,有效和激酶选择性抑制剂的发现。基于片段的筛选和设计原理导致了抑制剂系列的鉴定,并使用X射线晶体学分析了关键的结构变化。通过在吡唑环上的N1和C5 N位置进行关键取代,可以实现显着的激酶选择性和效力。桥连的双环吡唑并羧酰胺11代表RIP2的选择性和有效抑制剂,将允许更详细地研究RIP2抑制作为自身炎症性疾病的治疗靶标。